BPC-157
| Scientific name | Body Protection Compound 157 |
|---|---|
| Synonyms | Bepecin; PL 14736 |
| Abbreviation | BPC-157 |
| CAS Number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.53 g/mol (average) |
| Sequence (one-letter) | GEPPPGKPADDAGLV |
| Length | 15 residues |
| Origin | Synthetic pentadecapeptide fragment |
| PubChem CID | 9941957 |
Interactive sequence
Mechanisms under investigation
The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.
Target receptors / systems studied
Evidence base (transparent counts)
Research timeline
- 1991 — Body Protection Compound family described from gastric juice protein.
- 1999 — Early preclinical characterization of the BPC-157 fragment in animal models.
- 2010 — Expanded studies of angiogenic and connective-tissue endpoints in rodents.
- 2020 — Mechanistic (VEGFR2 and nitric oxide) and cellular-model investigations plus reviews.
Selected literature
Filter by study model. Each record is classified for the evidence base above.
Each record maps to a structured evidence row with study model, species, and support level.
Handling and reference
Storage
Lyophilized: store at -20 C protected from light. Reconstituted: refrigerate and use within the reported stability window.
Stability
Lyophilized powder is comparatively stable; reconstituted solutions are more labile and sensitive to temperature and freeze-thaw.
Solubility
Reported soluble in water; contains no cysteine disulfide bridges.
Handling
Use aseptic technique; swirl gently rather than vortexing. For in vitro / research use only.
Molecular weight calculator
Average-mass estimate from a one-letter sequence.
Reconstitution calculator
Laboratory concentration only. Not dosing guidance.
What is BPC-157?
What research models has it been studied in?
Is there controlled human clinical trial evidence?
How is it stored and handled in a laboratory?
Is this intended for human use?
Research material & documentation
This profile is an educational reference. Lot-level laboratory documentation for materials supplied by Peptide Titans is published openly.
BPC-157 research material → · Lot-specific Certificates of Analysis → · How lots are tested →
Evidence records
- Synthesis of BPC-157 preclinical pharmacology and healing mechanisms (2018) — review — PubMed.
- In vitro study examining tendon fibroblast outgrowth and growth hormone receptor expression following BPC-157 exposure. (2014) — in vitro — PubMed.
- Preclinical rat study reporting muscle-to-bone junction healing endpoints after BPC-157 administration. (2012) — in vivo — PubMed.
- Preclinical rodent study examining angiogenesis and VEGFR2 signalling in an injury model following BPC-157 administration. (2007) — in vivo — PubMed.
- Modulates nitric oxide system in cultured endothelial cells (2003) — in vitro — PubMed.
- Gastric mucosa protection in rodent ulcer models (2001) — in vivo — PubMed.
Every record carries a study model, species, support level and review status in the evidence table. Terms used throughout these profiles are defined in the peptide research glossary.
Citation generator
Explore the full research database
Browse peptide profiles, publications, and laboratory references — all research-only.